Gravity Diagnostics, LLC

Gravity Diagnostics, LLC was paid $116.16M by Medicaid between Jan 2018 and Dec 2024, across 153 billing codes. Its largest line is G0481, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed — 30% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Kentucky

Rank by total paid#1 of 73

Median peer was paid$95K

This provider vs. median1,224×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	105,251	$1.15M
2019	143,766	$2.94M
2020	239,833	$6.32M
2021	289,315	$7.14M
2022	790,310	$24.76M
2023	1,224,145	$41.49M
2024incomplete	978,980	$32.35M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	30%	627,615	280,579	$35.11M
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	22%	895,937	395,023	$25.53M
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	12%	256,470	102,284	$14.40M
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	8.5%	216,003	103,932	$9.82M
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	6.6%	123,968	57,115	$7.72M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	4.1%	103,083	71,160	$4.81M
86481		1.3%	31,169	29,005	$1.51M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	1.3%	58,351	21,554	$1.48M
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	1.0%	56,293	49,675	$1.17M
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	55,701	49,140	$1.15M
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	55,132	48,618	$1.09M
87563		<1%	44,544	39,227	$864K

141 more codes

U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	51,756	$781K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	62,254	$772K
86480		<1%	18,484	$607K
87631		<1%	13,568	$579K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	<1%	7,441	$566K
87522	Neg quan hep c or qual rna	<1%	25,674	$541K
86803		<1%	53,704	$450K
86780		<1%	65,818	$444K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	5,109	$389K
G0499	Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result	<1%	21,095	$342K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	27,909	$341K
80053	Comprehensive metabolic panel	<1%	57,782	$335K
80050	General health panel	<1%	8,208	$300K
84443	Thyroid stimulating hormone (TSH)	<1%	31,154	$300K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	9,905	$275K
81226		<1%	4,617	$249K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	55,688	$244K
80074		<1%	16,532	$236K
82607		<1%	23,081	$188K
80061	Lipid panel	<1%	23,049	$174K
87340		<1%	30,311	$167K
87529		<1%	8,935	$163K
87581		<1%	16,101	$158K
87486		<1%	15,866	$155K
81225		<1%	4,305	$155K
87541		<1%	15,482	$149K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	13,346	$148K
86705		<1%	19,307	$143K
87511		<1%	8,076	$119K
83036	Hemoglobin; glycosylated (A1C)	<1%	26,274	$114K
87640		<1%	11,783	$105K
86706		<1%	16,039	$87K
81227		<1%	3,365	$71K
86704		<1%	11,486	$71K
36415	Collection of venous blood by venipuncture	<1%	13,936	$68K
82248		<1%	20,662	$64K
83735		<1%	11,575	$60K
81025		<1%	14,243	$60K
81230		<1%	2,313	$55K
80048	Basic metabolic panel (calcium, ionized)	<1%	13,722	$53K
81231		<1%	2,145	$52K
84481		<1%	5,802	$49K
81328		<1%	1,547	$44K
87641		<1%	3,838	$39K
84439		<1%	10,136	$39K
80373		<1%	15,188	$32K
80364		<1%	9,892	$31K
80372		<1%	14,216	$31K
80355		<1%	13,845	$31K
80354		<1%	15,076	$31K
80366		<1%	12,216	$29K
84460		<1%	12,001	$28K
82247		<1%	11,877	$27K
84450		<1%	11,997	$27K
83992		<1%	12,045	$25K
81479	Unlisted molecular pathology procedure	<1%	19,518	$23K
87521	Neg quan hep c or qual rna	<1%	1,508	$23K
82746		<1%	5,484	$21K
80368		<1%	11,052	$21K
81291		<1%	2,315	$20K
87086	Culture, bacterial; quantitative colony count, urine	<1%	4,633	$20K
85027		<1%	7,083	$20K
80348		<1%	10,646	$20K
84155		<1%	11,883	$19K
80357		<1%	10,064	$19K
84403		<1%	1,696	$19K
80367		<1%	9,218	$17K
81355		<1%	1,376	$17K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	189	$17K
82670		<1%	1,258	$17K
80361		<1%	5,643	$17K
80360		<1%	10,115	$16K
84075		<1%	6,977	$16K
80346		<1%	5,686	$15K
84702		<1%	2,340	$14K
81241		<1%	1,223	$14K
83540		<1%	4,322	$14K
84146		<1%	1,557	$13K
84466		<1%	2,153	$13K
81240		<1%	1,224	$12K
80365		<1%	5,349	$12K
84144		<1%	1,183	$12K
82627		<1%	1,065	$11K
80370		<1%	5,749	$11K
87632		<1%	139	$10K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	308	$10K
84270		<1%	892	$9K
80349		<1%	4,400	$9K
80338		<1%	5,193	$9K
80324		<1%	5,533	$9K
82040		<1%	4,894	$9K
80333		<1%	3,457	$9K
80353		<1%	4,227	$9K
80076		<1%	2,574	$9K
80337		<1%	3,452	$9K
86709		<1%	1,732	$8K
80356		<1%	3,473	$7K
80359		<1%	3,307	$7K
87186		<1%	1,274	$6K
83001		<1%	791	$6K
83002		<1%	789	$6K
82728		<1%	953	$6K
80369		<1%	3,936	$6K
81401		<1%	287	$6K
87077		<1%	1,304	$6K
80358		<1%	3,120	$6K
86592		<1%	2,347	$5K
80164		<1%	857	$5K
84153		<1%	628	$5K
80375		<1%	1,863	$3K
80323		<1%	1,794	$3K
87341		<1%	633	$3K
80342		<1%	2,115	$3K
80371		<1%	1,596	$3K
84100		<1%	1,073	$3K
80362		<1%	3,053	$3K
86593		<1%	1,050	$2K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	162	$2K
80178		<1%	598	$2K
83550		<1%	512	$2K
81003		<1%	1,654	$2K
84436		<1%	579	$2K
82533		<1%	204	$1K
84480		<1%	283	$1K
83690		<1%	710	$1K
87481		<1%	153	$1K
86376		<1%	184	$1K
82150		<1%	678	$1K
83525		<1%	249	$1K
86140		<1%	375	$913.24
85610		<1%	179	$367.76
84681		<1%	54	$353.51
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	16	$168.48
82977		<1%	32	$102.77
80069		<1%	12	$53.21
87501		<1%	28	$18.47
81418		<1%	148	$0.35
80363		0%	2,571	$0.00
80321		0%	163	$0.00
80326		0%	41	$0.00
80325		0%	420	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialREMINGTON, ANTHONY (CEO)